USA Equities (OTCMKTS:USAQ) Upgraded to “Hold” by Zacks Investment Research

USA Equities (OTCMKTS:USAQGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports.

According to Zacks, “American Biogenetic Sciences, Inc. is engaged in researching, developing and marketing cardiovascular and neurobiology products for commercial development. The company’s products are designed for in vitro and in vivo diagnostic procedures and therapeutic drugs. At the present time The company’s principal products or activities are: the Thrombus Precursor Protein Diagnostic Test; the Functional Intact Fibrinogen Diagnostic Test; Therapeutic Neurocompounds; In Vitro Diagnostic Products For Ifectious And Auto-Immune Disease; and Mouse Serum “

Separately, Litchfield Hills Research reiterated a “buy” rating on shares of USA Equities in a report on Monday, February 28th.

USAQ opened at $0.55 on Thursday. The business has a 50 day simple moving average of $0.53 and a two-hundred day simple moving average of $0.62. The company has a quick ratio of 0.43, a current ratio of 0.51 and a debt-to-equity ratio of 0.61. USA Equities has a one year low of $0.23 and a one year high of $1.00.

USA Equities Company Profile (Get Rating)

USA Equities Corp., a medical device technology and software as a service (SaaS) company focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine.

Featured Articles

Get a free copy of the Zacks research report on USA Equities (USAQ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for USA Equities Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USA Equities and related companies with MarketBeat.com's FREE daily email newsletter.